Development of new anti-tuberculosis drugs: the strategy of unconventional microbial culture and silencing gene activation.

Tieshan TENG; Longxiang XIE; Jianping XIE

Return

Development of new anti-tuberculosis drugs: the strategy of unconventional microbial culture and silencing gene activation.

Author: Tieshan TENG ¹ ; Longxiang XIE ¹ ; Jianping XIE ²
Author Information

1. Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, Henan, China.
2. State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, Institute of Modern Biopharmaceuticals, School of Life Sciences, Southwest University, Chongqing 400715, China.
Publication Type:Journal Article
Keywords: Mycobacterium tuberculosis; one strain-many compounds (OSMAC); silent genes; un-cultured microorganisms
From: Chinese Journal of Biotechnology 2018;34(8):1306-1315
CountryChina
Language:Chinese
Abstract: Tuberculosis (TB), caused by Mycobacterium tuberculosis, has become a major human infectious disease. The existing first-line and second-line TB drugs have poor treatment outcomes in patients with MDR-TB and XDR-TB. There is an urgent need for new and better drugs to treat tuberculosis due to lengthy and complex treatment regimens and a rising problem of drug resistance. Microbial-derived natural products have revealed enormous reservoirs of as yet untapped lead compounds. In this review, we discuss the strategies that have been developed in bacteria and fungi to isolation of non-culturable microorganisms and activation of silent biosynthetic gene clusters involved in the study of microbial-derived natural products. This review also highlights recent advances in microbial-derived natural products with anti-tuberculosis activity using these methods.